Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2011 2
2012 2
2014 2
2016 2
2017 2
2018 2
2019 1
2020 4
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
Pistillo MP, Carosio R, Grillo F, Fontana V, Mastracci L, Morabito A, Banelli B, Tanda E, Cecchi F, Dozin B, Gualco M, Salvi S, Spagnolo F, Poggi A, Queirolo P. Pistillo MP, et al. Among authors: gualco m. Clin Immunol. 2020 Jun;215:108428. doi: 10.1016/j.clim.2020.108428. Epub 2020 Apr 25. Clin Immunol. 2020. PMID: 32344017
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization.
Mastracci L, Fontana V, Queirolo P, Carosio R, Grillo F, Morabito A, Banelli B, Tanda E, Boutros A, Dozin B, Gualco M, Salvi S, Romani M, Spagnolo F, Poggi A, Pistillo MP. Mastracci L, et al. Among authors: gualco m. Cancer Immunol Immunother. 2020 Apr;69(4):653-662. doi: 10.1007/s00262-020-02494-y. Epub 2020 Feb 5. Cancer Immunol Immunother. 2020. PMID: 32025849 Free PMC article.
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.
Bruno W, Martinuzzi C, Dalmasso B, Andreotti V, Pastorino L, Cabiddu F, Gualco M, Spagnolo F, Ballestrero A, Queirolo P, Grillo F, Mastracci L, Ghiorzo P. Bruno W, et al. Among authors: gualco m. Oncotarget. 2018 Jun 19;9(47):28798. doi: 10.18632/oncotarget.25684. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983899 Free PMC article.
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.
Bruno W, Martinuzzi C, Dalmasso B, Andreotti V, Pastorino L, Cabiddu F, Gualco M, Spagnolo F, Ballestrero A, Queirolo P, Grillo F, Mastracci L, Ghiorzo P. Bruno W, et al. Among authors: gualco m. Oncotarget. 2017 Dec 14;9(5):5691-5702. doi: 10.18632/oncotarget.23204. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464027 Free PMC article.
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, Cabiddu F, Gualco M, Ballestrero A, Bianchi-Scarrà G, Queirolo P, Grillo F, Mastracci L, Ghiorzo P; Italian Melanoma Intergroup (IMI). Bruno W, et al. Among authors: gualco m. Oncotarget. 2017 Jan 31;8(5):8069-8082. doi: 10.18632/oncotarget.14094. Oncotarget. 2017. PMID: 28039443 Free PMC article.
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
Manzini C, Venè R, Cossu I, Gualco M, Zupo S, Dono M, Spagnolo F, Queirolo P, Moretta L, Mingari MC, Pietra G. Manzini C, et al. Among authors: gualco m. Oncotarget. 2016 Sep 20;7(38):60858-60871. doi: 10.18632/oncotarget.11504. Oncotarget. 2016. PMID: 27563819 Free PMC article.
19 results